Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Becton Dickinson (NY: BDX )

241.74 +3.90 (+1.64%)
Official Closing Price Updated: 4:10 PM EDT, Jul 30, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,755,530
Open 236.99
Bid (Size) 226.50 (1)
Ask (Size) 245.00 (1)
Prev. Close 237.84
Today's Range 236.99 - 242.25
52wk Range 218.75 - 284.48
Shares Outstanding 287,190,180
Dividend Yield 1.51%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Key Takeaways From Becton Dickinson Analyst Ratings
Via Benzinga
Insulin Device Maker Embecta Weighs Sale After 70% Share Decline Following Becton Dickinson Spin-Off
Embecta is exploring a potential sale after a nearly 70% drop in share price since its spin-off from Becton Dickinson. The company's U.S. business has struggled with the rise of GLP-1 drugs and... 
Via Benzinga

Performance

YTD
-1.50%
-1.50%
1 Month
+5.44%
+5.44%
3 Month
+3.56%
+3.56%
6 Month
+1.64%
+1.64%
1 Year
-13.24%
-13.24%

More News

Read More
Looking Into Becton Dickinson's Recent Short Interest
Via Benzinga
3 Healthcare Stocks to Buy Now to Profit From Aging Population Trends
Via InvestorPlace
Topics Retirement
Exposures Pension
UnitedHealth, Edwards Lifesciences, First Citizens Bank And More: CNBC's 'Final Trades'
Via Benzinga
Peering Into Becton Dickinson's Recent Short Interest
Via Benzinga
Looking Into Becton Dickinson's Recent Short Interest
Via Benzinga
Peering Into Becton Dickinson's Recent Short Interest
Via Benzinga
Boing! 7 Undervalued Stocks That Could Surprise the Skeptics.
Via InvestorPlace
Stock Market Revs To Highs On Nvidia, CrowdStrike, Yields: Weekly Review
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
BD Bolsters Portfolio With $4.2B Cash Deal For Edwards Lifesciences' Critical Care Group: Details
Via Benzinga
Edwards Lifesciences Stock Nears Breakout On A Surprise $4.2 Billion Deal
Via Investor's Business Daily
Trade Winds Turning: 3 Stocks Poised to Gain from Biden’s China Tariffs
Via InvestorPlace
Topics World Trade
Exposures Tariff
Biden's New Tariffs On Chinese Imports Are A 'Clear Giveaway' To These Two Tesla Rivals, Jim Cramer Says: 'I Like This Policy'
Via Benzinga
Topics World Trade
Exposures Tariff
MarketBeat Week in Review – 4/29 - 5/3
Via MarketBeat
Topics Economy Stocks
Exposures Interest Rates US Equities
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Becton & Dickinson 'Is Well On Its Way To Achieving 2025 Commitments,' Analyst Optimistic On Outlook
Via Benzinga
BDX Stock Earnings: Becton, Dickinson Beats EPS, Beats Revenue for Q2 2024
Via InvestorPlace
Boston Scientific Bucks the Medtech Slow Down and Raises Outlook
Via MarketBeat
How Much Will $10k Invested in These Dividend Aristocrats Grow to by 2025?
Via InvestorPlace
Rich Returns at a Discount: 3 Dividend Aristocrats Trading at 52-Week Lows
Via InvestorPlace
AngioDynamics Resolves Decade-Long Patent Litigation With Becton, Dickinson In Settlement Agreement
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Should You Buy Solventum (SOLV) Stock After the 3M Spinoff?
Via InvestorPlace
Jim Cramer Says Don't Sell This Beauty Brand, Believes KKR And Blackstone 'Can Make More Money'
Via Benzinga
Becton, Dickinson And Co. Dividend Stock Analysis
Via Talk Markets
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.